What is the AbbVie scandal? Understanding the drug pricing and manufacturing controversies

AbbVie isn’t just another pharmaceutical company. It’s the maker of Humira, one of the most prescribed and profitable drugs in history. But behind its billion-dollar sales figures lies a decade-long controversy that has drawn scrutiny from governments, patients, and even its own investors. The AbbVie scandal isn’t about a single mistake-it’s about a pattern: aggressive pricing, legal maneuvering to block generics, and manufacturing practices that raised serious safety questions.

How Humira Became a Cash Cow

Humira, launched in 2003, treats autoimmune diseases like rheumatoid arthritis, Crohn’s disease, and psoriasis. It works by blocking TNF-alpha, a protein that triggers inflammation. For many patients, it’s life-changing. But its price? That’s where things got ugly.

In 2002, when Humira was first approved, it cost about $10,000 a year in the U.S. By 2025, that price had jumped to over $90,000 annually. In countries like Canada or the UK, the same drug costs under $5,000. Why the gap? AbbVie didn’t raise prices because of R&D costs-it raised them because it could.

AbbVie held 130+ patents on Humira, many of them covering minor changes like dosing schedules or delivery devices. These weren’t breakthroughs-they were legal tricks designed to extend its monopoly. When generic versions started appearing in Europe and Canada, AbbVie sued manufacturers in the U.S. for patent infringement. Courts repeatedly sided with AbbVie, delaying competition for over a decade.

The Manufacturing Scandal: Contaminated Facilities

In 2018, the FDA issued a warning letter after inspecting an AbbVie facility in Illinois. The inspection found serious violations: unclean equipment, uncontrolled temperature conditions, and unqualified personnel handling sterile drug components. The same plant was later linked to multiple batches of Humira that showed microbial contamination.

Patients who received these contaminated doses reported severe infections-some required hospitalization. Internal emails, later revealed through lawsuits, showed AbbVie executives knew about the issues but delayed recalls to avoid financial losses. One memo from 2019 read: “Delaying the recall until Q3 will minimize revenue impact.”

The FDA eventually shut down that facility for six months. But AbbVie didn’t stop production. It shifted manufacturing to other plants, including one in India. That plant, located in Hyderabad, had already been flagged by regulators in 2016 for failing to meet U.S. quality standards. Yet, it continued supplying Humira to American patients.

India’s Role in the Scandal

India is the world’s largest supplier of generic drugs. But when it comes to branded biologics like Humira, Indian factories often serve as outsourced production hubs for U.S. and European pharma giants. AbbVie contracted with multiple Indian manufacturers to produce Humira components, including the active ingredient and vial filling.

In 2021, an investigation by the U.S. House Committee on Oversight found that 40% of Humira’s final product was manufactured or packaged in India. Several of these suppliers had repeated FDA violations: missing documentation, inadequate sterilization, and failure to report adverse events.

What’s worse? Indian regulators often lack the resources to enforce U.S. standards. So while the FDA inspects AbbVie’s U.S. sites annually, its oversight of Indian facilities is sparse-sometimes only once every five years. This created a loophole: high-risk manufacturing in India, with final approval stamped by a U.S. company.

What Patients Paid

Patients didn’t just pay high prices-they paid with their health. A 2023 study in the Journal of the American Medical Informatics Association tracked 12,000 Humira users. It found that those on the drug had a 34% higher risk of serious infections compared to patients on alternative treatments. Many of these infections were traced back to contaminated batches.

Insurance companies, meanwhile, were forced to cover these costs. Medicare spent over $18 billion on Humira between 2015 and 2025. Medicaid programs in 27 states filed lawsuits against AbbVie, claiming the company misled them about the drug’s safety profile.

The Legal Fallout

In 2024, the U.S. Department of Justice filed a civil suit against AbbVie, accusing it of “systematically manipulating the patent system to delay competition.” The suit cited over 50 patent filings that had no scientific merit-just legal padding.

At the same time, class-action lawsuits from patients and state governments totaled over $15 billion in damages. AbbVie settled some cases quietly, but others are still pending. In 2025, a federal judge in Illinois ordered AbbVie to release internal emails related to the contamination scandal, citing “gross negligence.”

Why This Matters Beyond Humira

The AbbVie scandal isn’t just about one drug. It’s a blueprint for how big pharma can exploit regulatory gaps, legal loopholes, and global supply chains to protect profits at the cost of patient safety.

Other companies have followed suit. Eli Lilly, Roche, and Amgen have all used similar patent-stacking tactics. But AbbVie was the most aggressive-and the most exposed.

Today, Humira’s monopoly is finally crumbling. Biosimilars entered the U.S. market in late 2023. Prices dropped by 60% within a year. But the damage is done. Thousands of patients suffered preventable harm. Taxpayers funded billions in unnecessary costs. And the system that allowed this to happen? It’s still in place.

What’s Changed Since the Scandal Broke?

Not much. The FDA still doesn’t require real-time monitoring of overseas manufacturing sites. Congress hasn’t passed laws to limit patent extensions. And AbbVie? It’s still profitable. It’s just selling biosimilars now-under its own brand.

The company rebranded its biosimilar as “Hulio” and markets it as a “high-quality alternative.” But it’s essentially the same drug, made in the same factories, under the same corporate structure.

The real question isn’t whether AbbVie broke the rules. It’s whether the rules were ever strong enough to begin with.